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Background: Major haemoglobinopathies (MH), such as thalassaemia syndromes (Thal) and sickle cell disorders
(SCD), are genetic defects associated with chronic anaemia and other complications. In Europe, MH are rare
diseases (RD) but their prevalence is significantly growing in many countries due to mobility and migration flows.
This creates a growing health problem in the EU that has not yet been effectively addressed by Member States
(MS) authorities. The present study has been conducted with the aim of: (i) providing an overview of policies for
MH in 10 EU member states (MS) (ii) analysing the challenges linked to these RD due to growing requirements
imposed by population, mobility and migration trends and (iii) identifying gaps, proposing improvements on
existing policies, or developing new ones to fit the identified needs.
Methods: The study has been undertaken by a group of members of the European Network for Rare and Congenital
Anaemias (ENERCA) and the Thalassaemia International Federation (TIF), in collaboration with the public affairs firm
Burson-Marsteller Brussels. Data from 10 EU countries have been gathered using targeted desk research and one-to-one
interviews with local stakeholders, including healthcare professionals, patients and public health officers/providers.
Results: 1. MH are the most common RD in all the 10 countries, 2. Data on prevalence, overall burden, trends, and
clinical follow up costs are lacking in most countries. 3. Neonatal screening practices show a wide variation across and
within countries. 4. Awareness on MH and their related complications is very low, exception made of Italy, Greece,
Cyprus and UK, 5. No disaggregated data is available to understand the impact of mobility and migration on the
prevalence of haemoglobinopathies, and how healthcare delivery systems should adapt to respond to this situation. 6.
Targeted policy measures and/or actions are generally lacking and/or delayed.
Conclusions: Ten policy recommendations have been drawn from this study, building on 2006 WHO recommendations
for MH to include haemoglobinopathies in National Plans of Actions for Rare Diseases.
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recommendationsBackground
Major Haemoglobinopathies (MH), mainly thalassaemia
syndromes (Thal) and sickle cell disease (SCD) are rare
genetic blood disorders that affect more than 330,000
newborns every year worldwide. From these, about 70%
suffer from SCD, and the remaining, from severe forms
of Thal [1]. The World Health Organization (WHO) has
stressed that haemoglobinopathies are a growing health* Correspondence: jlvives@clinic.ub.es
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article, unless otherwise stated.problem in 71% of 229 countries, which account for 89%
of all births worldwide, mostly in low and middle in-
come countries [2]. Their prevalence, however, varies
considerably between the different regions of the world,
between countries in the same region, between areas
within a country, and even, between different medical
centres within the same area (2). These disorders are en-
demic in the Mediterranean, African and Asian regions;
and are currently the most common rare diseases (RD)
of genetic origin in Europe [3,4].
In addition to severe anaemia, both Thal and SCD, can
lead to chronic complications that severely undermined Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(Table 1). If untreated, patients with thalassaemia major
usually die during childhood or before adolescence.
Transfusion therapy has resulted in increased life ex-
pectancy; however, patients develop iron overload and
related complications in the cardiac, hepatic and endo-
crine system. In addition, patients may develop infec-
tions, mainly transfusion related (e.g. Hepatitis B and C),
bone abnormalities and osteoporosis. In SCD, patients
suffer from chronic or acute anaemia due to increased
haemolysis, but also from adverse events related to hy-
perviscosity and vaso-occlusion. Clinical manifestations
include acute pain (vaso-occlusive crisis), hyposplenism
due to multiple splenic microinfarcts, acute chest syn-
drome, osteonecrosis, nephropathy, proliferative retinop-
athy, leg ulcers, severe vasculopathy and cerebrovascular
disease. Patients with SCD are similarly at increased risk
of infections related to hyposplenism [5-7].
Through mobility and migration flows, haemoglobino-
pathies have spread from the Mediterranean, Africa and
Asia to the whole Europe, the Americas and Australia,
and there is scientific evidence that they have become a
global public health problem. Because they are endemic
or have expanded following mobility flows, haemoglobi-
nopathies are present in all European countries creating
an important impact on health services [4]. However,
there are still poor data on the precise prevalence, over-
all burden, and trends of the diseases, due to a lack of
comprehensive data collection and analysis systems in
the different European countries.
As the consequence of medical advances in the last
decades, haemoglobinopathies can be effectively pre-
vented, early and specifically diagnosed, and treated
appropriately, as a mean to prevent secondary com-
plications and increase patients’ life expectancy or
quality of life [8,9]. Accordingly, in countries with exist-
ing standards of care and where management guidelines
have been implemented and well adhered to by patients,
the rate of survival and quality of life has significantly
increased.Table 1 Co-morbidities and/or complications caused by majo
Thalassaemia major and intermedia Si
Chronic Anaemia (if untreated) Ch
Ac
sp
Iron overload (from the disease or blood transfusion) and its
complications in the cardiac, hepatic and endocrine system
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Increased risk of infections (mainly transfusion related e.g.
Hepatitis B and C)
In
tra
Bone abnormalities and osteoporosis RiPrevention and management of haemoglobin disorders
is well established and managed in countries where these
conditions were traditionally endemic (e.g. Cyprus,
Greece, Italy) or in countries that have a longstanding
tradition of receiving migrants (e.g., France and the UK).
However, current and future mobility and migration
flows to and within regions including the European
Union (EU), pose considerable new challenges that have
to be taken into consideration by members states (MS)
and EU authorities. In a number of Europe countries,
with “low incidence rates” of haemoglobinopathies, the
evidence shows that migrant population groups (e.g. pop-
ulations from Southern Europe, North Africa, Southern
Asia and Southeast Asia) are under-diagnosed, and par-
ticular care needs are not sufficiently recognised and em-
bedded into healthcare delivery systems [10-13].
The aim of this study was to analyse and evaluate
current health and social policies affecting patients with
MH in 10 European countries, to identify main policy
gaps and best practices, and, based on these, to suggest
potential actions. Ten essential recommendations for
policy actions have been put forward for consideration
by the EU, national governments, health authorities and
providers.
Methods
The study focused on the following EU Member States
(MS): Belgium, Cyprus, France, Germany, Greece, Italy,
the Netherlands, Spain, Sweden and the UK. It was
undertaken, between March and October 2012, by a
group of members of the European Network on Rare and
Congenital Anaemias (ENERCA), specialized in the field of
haemoglobinopathies, and the Thalassaemia International
Federation (TIF), in collaboration with Burson-Marsteller
Brussels, a public affairs and communication agency.
Through desk research and performing interviews
using a structured questionnaire (Additional file 1 rele-
vant information was gathered from each of the 10 MS
with regard to the prevalence of Thal and SCD, existing
guidelines and practices at national or regional level,r haemoglobin disorders
ckle-cell disease
ronic anaemia
ute anaemia (increase haemolysis, bone marrow suppression, blood loss,
leen sequestration, malarial infection, etc.)
verse events related to hyperviscosity and vaso-occlusive crisis (Acute pain,
ute chest syndrome, hyposplenism, nephropathy, proliferative retinopathy,
c.) and haemolysis and vasculopathy (Pulmonary hypertension; priapism, leg
cers and cerebrovascular disease)
creased risk of infections related to hyposplenism (And to transfusions in
nsfused patients)
sk of osteonecrosis
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ders. Information came from a range of sources includ-
ing the local governments, patient’s associations, policy
documents, scientific literature and media reports.
Building on the desk research undertaken, one-to-one
interviews were carried out in each of the ten countries,
with three to four national stakeholders from relevant
government services, physicians and other healthcare
professionals, patients and families. While attempts were
made to consult a range of stakeholder groups in the
preparation of each country report, exceptionally re-
sponses from all groups, including government officials,
were not available within the given time period in all
countries. In such situations, the reports were written on
the basis of the best information available through the
desk research and other interviews.
On the basis of the gathered information, individual
country reports were built. The information was struc-
tured as follows: (i) Key facts and figures, (ii) Policy
focus, (iii) Prevention and screening, (iv) Treatment and
care, (v) Policy outlook and (vi) Interviewee’s suggested
policy actions.
Results and discussion
According to the World Health Organization (WHO),
approximately 5% of adults, in the word, are carriers for
a haemoglobin disorder, 2.9% for thalassaemia and 2.1%
for SCD [1]. Moreover, over 300,000 children are born
each year with a MH, 30% are born with Thal, while 70%
have SCD. With worldwide migration, these diseases are
as much a feature of Europe, the United States and
Australia as of the countries where they originated,
representing a growing health problem in 71% of 229
countries, which account for 89% of all births.
Prevalence and burden of haemoglobinopathies and the
impact of migrations
The number of patients with haemoglobinopathies has
been estimated to be almost 44,000 in the 10 EU coun-
tries analysed in this survey, varying from 150 cases in
Sweden to 10,500 in France.. Recent migration flows to
and within the EU have increased the number of pa-
tients with haemoglobinopathies in many European
countries [3,4]. However, accurate, comprehensive and
disaggregated data is missing in the vast majority of the
countries in order to understand how mobility and mi-
grant flows are impacting haemoglobinopathies epidemi-
ology and how healthcare systems and policies are
responding to this. Even where data collection and ana-
lysis systems do exist, these do not address relevant mi-
gration and ethnic origins of patients comprehensively
through relevant disaggregated data, as recommended
by WHO [14,15]. Moreover, there are no direct cost esti-
mates available on the financial and social burden ofhaemoglobin disorders as compared to the long-term
costs associated to misdiagnosis and poor management of
the diseases. However lifetime treatment costs have been
estimated by health economists [16], which do confirm a
rising cost as patients grow older. The cost–effectiveness
of prevention has been studied more deeply [17,18].
Policy focus
There is a considerable absence of targeted and compre-
hensive policy measures across the 10 EU countries in-
cluded in this report, with some notable exceptions
(Table 2). In 2006, WHO, published two Resolutions ad-
dressing specifically the health needs on SCD and Thal
[19,20]. Despite this, the establishment of comprehensive
plans to address Thal and SCD is lacking in most of the
studied European MS, with the exception of five coun-
tries, of which three are countries where haemoglobin
disorders are endemic (Cyprus, Greece, Italy and France
and UK). These countries have specific strategies or pro-
grammes in place dedicated to haemoglobinopathies.
These include: the prevention and holistic management
of the diseases, screening, education and awareness mea-
sures and aim to take into account cultural practices to
a certain extent. Accordingly, in only two of the studied
EU countries where these disorders are mainly imported
via migrations, they remain a secondary priority for pol-
icy action and, in countries where actions do exist, these
are fragmented. Moreover, there is no particular refer-
ence or focus within RD strategies or migrant health ini-
tiatives on haemoglobin disorders. Reluctance or delay
from governments to take targeted action to address
MH effectively may be partly attributed, depending on
the countries, to the underestimation of the burden of
these diseases and of the costs associated with poor or
inadequate screening, diagnosis and clinical management.
More recently, cost-containment measures in healthcare
budgets, as well as outstanding ethical, legal and social
concerns linked to screening and prevention of genetic
disorders, have further contributed to the governments’
reluctance to take action. In addition, structured dialogue
between governments and the relevant healthcare commu-
nities or patient’s associations is very limited or, in most
countries, inexistent.
Prevention and diagnosis
Screening practices vary across and within the countries
surveyed, and it was found that they generally target the
population considered at risk, or being carriers of the
disease (Table 2). In most cases, screening is not struc-
tured and comprehensively implemented within coun-
tries and is dependent on the knowledge and education
of both healthcare professionals and patients. At risk
population is generally defined by ancestors’ origin or
ethnicity, based on physical appearance or presumption
Table 2 Haemoglobinopathies: summary indicators in 10 European countries
Haemoglobinopathies report summary of indicators
Country Perceived influence
of migration on
epidemiology
National/ local
THAL registry
National/local
SCD Registry
Structured national
neonatal screening
programme
Structured national
antenatal screening
programme
National/regional
rare disease plan
expected by
Haemoglobin disorders
focused plans or focus
in rare disease plans
Reimbursement
of treatments
Country
awareness
Belgium high influence no national local No rules yes, work in
progress
no yes low
Cyprus low influence
traditionally, but
increasing
national no no Yes, by church and civil
authorities (for the
Turkish community)
yes approval
planned in 2013
yes yes very good
France high influence national local National, targeted
to the at risk
population
Antenatal diagnosis
available upon
request
Yes (already
implementd)
yes partly low
Germany high influence no no no (trial Berlin) no yes, work in
progress 2013
N/A partly very low
Greece low influence:
disorders linked
to indigenous
to population
National
(on Haemoglobinopathies)
yes yes yes yes yes (for insured
patients and
asylum seekers)
high to some
extent only
Italy low influence:
disorders linked
to indigenous
to population
regional
(on Haemoglobinopathies)
local/regional local/regional yes, work in
progress 2013
N/A yes (depending
on the region)
generally low,
high in specific
regions
The Netherlands high influence local local yes yes yes, work in
progress 2013
N/A yes low
Spain high influence National
scientific
registry not
official
National
paediatric
scientific
registry
regional No rules yes no In general yes,
some regions
partially
low
Sweden high influence no no no no yes, work in
progress 2013
N/A yes very low
UK high influence yes yes yes yes yes, work in
progress 2013
yes yes relatively high
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ceptionally there are clear guidelines to define screening
target population. In the UK, experiments of screening
based on historical environmental exposure and a tar-
geted questionnaire has been established in order to im-
prove screening coverage [21]. Haemoglobinopathies are
usually not covered in medical undergraduate curricula,
and awareness of the risks of being a carrier, affected
birth rates, associated health risks and sequels and how
to prevent and manage haemoglobin disorders, were low
among the general population. Language barriers and
poor multicultural competencies of healthcare staff and
support teams were also considered critical factors lead-
ing to under or misdiagnosis, poor disease management
and patient adherence with treatment, lower patient safety
and patient awareness. Only a few countries, including
Cyprus, Greece, Italy, Belgium and the UK, have national
or local targeted education and awareness campaigns to
prevent haemoglobin disorders amongst the general popu-
lation. Such campaigns were mostly driven by patient sup-
port organisations in France, the Netherlands, Spain and
the UK. In Cyprus, Greece and Italy, there have been suc-
cessful prevention experiences by raising general aware-
ness with the involvement of the broader community
(educational and religious bodies) [9,22].
Treatment and care
Based on the retrieved country policies or on the inter-
views performed in each country with governments,
health professionals or patient support groups, it appears
that patients with haemoglobin disorders are generally
treated by specialist doctors in hospitals or dedicated
centres. Timely, regular access to specialist care, innova-
tive monitoring methods for diagnosis and treatment
outcomes varies across and within countries with health-
care cuts and specialist shortages being the main reasons
behind the variations. Specialist care and follow-up of
medical complications primary or secondary to the dis-
ease in the context of a multi disciplinary approach are
considered an essential component in the effective man-
agement of the haemoglobinopathies in order to reduce
mortality and health complications. However, due to a
multidisciplinary requirement, the approach to the care
of these patients is generally fragmented and coordin-
ation of specialists from different relevant disciplines is
often not structured. Specialist medical associations or
patients’ organizations like Thalassaemia International
Federation usually drive the preparation and publication
of guidelines and protocols. However, awareness of
health professionals and effective implementation across
the countries is inconsistent. The recognition of European
Reference Networks in rare diseases [23] may strongly fa-
cilitate the wide diffusion of good practices and up to date
standards of care. An example is the European Networkfor Rare and Congenital Anaemias (ENERCA) that has re-
cently published guidelines for the management of SCD in
adults and children [13] and is currently working on the
establishment of a European network of centres of expert-
ise on Rare Anaemias in Europe [24].
Social support
Interviews have also stressed the fact that psychological
and professional support to help patients improve their
quality of life and integrate into the labour market is
scarce, fragmented and often undertaken by the pa-
tients support group; and that it is often forgotten in
the management of these diseases. Financial support to
affected patients is habitually provided through general
support measures for people with disabilities, under na-
tional rules, but additional costs linked to care (e.g.
transport to hospitals for regular treatment) are often not
covered.
Conclusions
Policy recommendations
On the light of the results here obtained, 10 essential
policy recommendations can be drawn. Target groups,
means of implementation and potential obstacles for each
recommendation are summarized in Table 3:
1. Develop and effectively implement data collection
and analysis systems
2. Develop and implement targeted programmes to
address haemoglobinopathies
3. According to the specific national needs, provide for
adequate specific measures to address haemoglobin
disorders within the framework of National Rare
Disease Plans
4. Establish centres of reference or expertise according
to the recommendations for expert centres in Rare
Anaemias recognition published in ENERCA
WHITE BOOK [24]
5. Fund research on haemoglobinopathies
6. Implement and support education and awareness
measures targeted at the general public, haemoglobin
patients and potential carriers, including different
migrant and ethnic minority groups. Awareness is
particularly important in the promotion of effective
prevention and this should include professionals in
primary health care, as well as the general public.
A striking example of the importance of awareness
is the need to screen for these disorders in early
pregnancy so that prenatal diagnosis may be a
possible choice.
7. Implement and actively support targeted healthcare
professional education and training programmes
with a particular focus on the prevention, diagnosis
and management of haemoglobinopathies
Table 3 Ten major recommendations to improve diagnosis and care of patients with haemoglobin disorders in
European countries
Recommendation Target Means of implementation Potential obstacles to be
overcome
1. Develop and effectively implement
data collection and analysis systems
Health professionals, Ministry of
health, Epidemiologists
Establish registries and databases
to ensure adequate and consistent
collection and analysis of data
Financial, Ethical and legal
2. Develop and implement
targeted programmes to address
haemoglobinopathies
Heath professional, Specialized
physicians, Primary care doctors (for
the initial diagnosis and every day
follow up), Healthcare managers
Develop medical education,
professional guidance and protocols
on prevention, management and
treatment of Hb disorders, Improve
access to innovative screening such
as MRI or intracranial echo doppler
Financial
3. According to the specific national
needs, provide for adequate specific
measures to address haemoglobin
disorders in the framework of
National Rare Disease Plans
National health authorities,
Governments
Comprehensive action plan with
targeted actions and measurable
objectives; shaped in dialogue
with the healthcare community
and patients
Poor awareness of broader societal
burden of the diseases and impact
assessment of targeted plans
4. Establish centres of reference or
expertise for: Harmonized and easy
access to diagnosis, treatment and
specialised care and comprehensive
follow-up of patients, Preventing and
improving early and specific diagnosis
of haemoglobin disorders by the
development of newborn screening
programmes for sickle cell disease
where necessary and their protocols to
ensure consistent screening practices,
National health authorities,
Governments, National health
authorities, Governments,
Healthcare professionals and
managers
Adoption of ENERCA
recommendation for recognition
of Centers of Expertise at National
level
Lack or delayed implementation of
National Plans or Strategies for rare
diseases.
5. Fund research on
haemoglobinopathies
International, EU and national
authorities in charge of research
programmes, Pharmaceutical
companies
Rare Anaemias have to be included
in the European and National
Research Programmes
Financial restrictions
6. Implement and support education
and awareness measures targeted
at the general public, haemoglobin
patients and potential carriers,
including different migrant and
ethnic minority groups
General public, Patients, Patient
support groups, Health
professionals, National Health
Authorities
Effective information and education
measures should be tailored to the
different range of ethnic minority
groups. Easily accessible information
materials should be developed,
which target couples and children
and describe the most important
aspects of haemoglobinopathies
diagnosis and prevention.
Financial, Language and cultural
barriers
7. Implement and actively support
targeted healthcare professional
education and training programmes
with a particular focus on the
prevention, diagnosis and
management of haemoglobinopathies
European and national Scientific
Societies, Ministries of Health and
ministries of education
Increase the part given to rare
anaemias in the European
Haematology curricula and
continuing medical education
Lack of multicultural care
competencies development of
healthcare practitioners, Lack of
dedicated health professionals
8. Support the empowerment and
participation of patients and the
healthcare community
Patients Associations and Health
care Community
Increase of communication channels
between patients and professionals
and shape policies that respond to
the specific needs of patients with
haemoglobinopathies and develop
multicultural healthcare delivery
methods
Social and cultural inequalities
across Europe
9. Support the development and
implementation of guidelines and
standards of care and prevention of
haemoglobin disorders and linked
sequels
Scientific and professional societies
and National health care Authorities
Development of coordinated
activities between health
professionals and authorities for
improving the quality of healthcare
delivery
The existence of inequalities in the
health care provision across Europe
and within individual countries
10. Adopt specific measures aimed
at addressing healthcare staff
shortages
Health Authorities and Medical
Centres
Diversification of health staff origins,
increasing the professional/patients
ratio and assuring multidisciplinary
care
Lack of specialists and financial
restrictions
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patients and the healthcare community
9. Support the development and implementation of
guidelines and standards of care and prevention of
haemoglobindisorders and linked sequels
10. Adopt specific measures aimed at addressing
healthcare staff shortages
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